Engagement of the B-cell antigen receptor (BCR) initiated by the Src kinase Lyn triggers rapid signaling cascades, leading to proliferation, differentiation or growth arrest of B cells. The Janus kinase (JAK)-STAT (signal transducer and activator of transcription) pathway, activated through cytokine receptors, mediates similar responses. Hypothesizing that Src and JAK pathways engage in crosstalk in B-cell signaling, we studied wild-type and Lyn-null B-cell lines, which express BCR. We found that activated BCR results in tyrosine phosphorylation of JAK-STAT, which required Lyn. To confirm that STAT activation is not due to JAK, we cloned the chicken homologs of JAK1 and JAK2 and made their antisense constructs. In cells expressing antisense JAK1 and JAK2, tyrosine phosphorylation of STAT was not inhibited following BCR stimulation. Using activation loop-specific phosphotyrosine antibodies, we did not detect phospho-JAK1 and phospho-JAK2 after BCR stimulation. The JAK inhibitor AG490 did not inhibit the tyrosine phosphorylation of Lyn or STAT after BCR simulation. An in vitro phosphorylation assay showed that Lyn directly phosphorylates STAT3. In an electrophoretic mobility shift assay, BCR stimulation led to enhanced DNA binding of the STAT3 in DT40, but not in the Lynnull cells. We conclude that BCR engagement activates the STAT pathway via Lyn, independent of JAK.
Introduction
Following antigen binding, the B-cell antigen receptor (BCR) sets off a set of signaling pathways that lead to gene expression changes and determine that cell's fate. As a member of the multimeric immune receptor family, the BCR requires the recruitment of cytosolic protein tyrosine kinases (PTK) to trigger these events. The PTK Lyn, a member of the Src family, plays a central role in initiating B-cell signaling process by phosphorylating immunoreceptor tyrosine activation in the BCR complex or immunoreceptor tyrosine inhibitory motifs in other signaling molecules upon stimulation (DeFranco et al., 1995; Sarmay et al., 1997) . Lyn is also involved in the phosphorylation of Syk and Btk (Wahl et al., 1997; Keshvara et al., 1998) , additional PTK downstream of Lyn that diversifies BCR signaling and contributes to cell fate. To date, the activation of Janus kinases (JAKs) has not been reported for BCR. The JAKs play an essential role in cytokine receptor signaling, mainly through the STAT (signal transducer and activator of transcription) transcription factors. As the JAKs have not been implicated in BCR signaling, STAT activation via BCR has been largely ignored. Stimulation by BCR engagement of peripheral blood B lymphocyte led to rapid STAT activation, which could be enhanced with co-ligation of CD19 (Su et al., 1999) . A few reports however suggest that BCR engagement leads to delayed and indirect activation of the STATs (Karras et al., 1996a, b; Fan and Rothstein, 2001) .
Because of its properties in undergoing homologous recombination at high frequency and expressing the BCR (immunoglobulin (Ig)M isotype) on its surface, the avian B-cell line DT40 has been widely used to study the roles of specific genes in BCR signaling (Winding and Berchtold, 2001) . To determine components of Lyndependent signaling pathways, we used a chicken microarray to identify alterations in gene expression in the Lyn-null DT40 cells. Some of these genes formed a B-cell germinal center signature, consisting of genes encoding germinal center-associated nuclear protein (germinal center-associated DNA primase, GANP), CD74, CD22, NF-kB, elongation factor 1a, CD79b, octamer binding factor 1, IgH chain and stathmin (Mirnics et al., 2004) . Here, we sought to determine the role of JAK2 in DT40 cells activated via its endogenous BCR. Through both genetic and pharmacologic means, we found that BCR activates JAK1 and JAK2 as well as STAT1, STAT3 and STAT5. However, STAT activation occurred through Lyn. Lyn-dependent tyrosine phosphorylation of JAK involves tyrosine sites other than those in the critical activation loop. As BCR engagement of DT40 leads to cell cycle and growth arrest (Takata et al., 1994) , these genetic studies suggest novel pathways involving Lyn and STAT, independent of the JAKs.
Results
BCR induction of Jak and Lyn activation in wild-type DT40 and Lyn-null DT40 cells The DT40 cell line is a very useful cell line, because it expresses members of the Src, Tec/Btk, Syk and JAK PTK families, undergoes homologous recombination at high frequency to effect gene ablation and displays intact BCR responsiveness. Moreover, only one Src kinase, Lyn, is expressed, enabling the Lyn-null DT40 cells to serve as an experimental system to determine unique, non-redundant function of Src PTK in intracellular signaling. To determine the involvement of JAK and STAT in BCR signaling, we stimulated DT40 and Lyn-null DT40 cells with the anti-chicken IgM monoclonal antibody M4. Proteins were immunoprecipitated with specific anti-JAK antibodies and then blotted with the anti-phosphotyrosine antibody 4G10. Both JAK1 and JAK2 were rapidly and transiently tyrosine phosphorylated (Figure 1a and b). JAK3 demonstrated no activation (data not shown). This time course coincided with activation of the Src kinase Lyn, but autophosphorylation of Lyn persisted as demonstrated either by phospho-Src (Y416) which recognizes the comparable tyrosine residue on Lyn (Y397) (Figure 1c ) or by Lyn auto-kinase assay (Figure 1d ).
STAT phosphorylation by BCR in wild-type DT40 cells and the role of Lyn in phosphorylation of STAT Having demonstrated JAK1 and JAK2 activation following BCR engagement, we next sought to determine if STAT members were activated. Tyrosine phosphorylation of STAT3, STAT5 and STAT1 occurred in wildtype DT40 cells (Figure 2a-c) . STAT1 activation occurred rapidly (1 min). STAT3 and STAT5 activation showed similar kinetics, with maximal response occurring at 5 min. However, there was no tyrosine phosphorylation of STAT1, STAT3 and STAT5 in BCR-stimulated Lyn-null DT40 cells. To corroborate these findings, we next used the Src-specific inhibitor PD173952 and performed a dose-inhibition study on wild-type DT40 cells (Dorsey et al., 2002) . As shown in Figure 3a -d, the IC 50 for PD173952 for BCR-activated Lyn in DT40 cells was B1 mM. Treatment of wild-type DT40 cells with PD173952 resulted in similar dose inhibition of tyrosine phosphorylation of STAT3, STAT5 and STAT1. Because these studies suggested that Lyn played a non-redundant role in the tyrosine phosphorylation of STAT following BCR engagement, we sought to confirm this by introducing a kinaseinactive mutant of Lyn (LynK275R) into wild-type DT40 cells. Expression of LynK275R inhibited BCRstimulated tyrosine phosphorylation of STAT3, STAT5 and STAT1 (Figure 4) .
Phosphorylation of the JAKs through BCR compared to their phosphorylation through G-CSF Because these results suggested that either Lyn directly phosphorylated STATs or indirectly through JAK activation, we next determined if the Src inhibitor PD173952 affected JAK tyrosine phosphorylation. Interestingly, a similar dose inhibition of JAK tyrosine phosphorylation occurred (Figure 3e and f). JAK activation occurs when the tyrosine residues in the activation loop (Tyr1007, 1008 for JAK2 or Tyr 1022, 1023 for JAK1) undergo auto-or trans-phosphorylation. As there are 49 tyrosine residues in JAK2, it is possible that Lyn was phosphorylating residues other than these residues. To determine that, we studied the DT40GR cell line that has been engineered to express both the BCR and the human granulocyte colonystimulating factor (G-CSF) receptor. In G-CSF receptor signaling, JAK2 is directly activated (Nicholson et al., 1995) . We stimulated DT40GR with either M4 or G-CSF and determined the auto-phosphorylation state of the JAKs. Blotting of protein lysates by anti-phospho-JAK1 and anti-phospho-JAK2 demonstrated that stimulation with G-CSF, not M4, resulted in JAK1 and JAK2 tyrosine phosphorylation (Figure 5a and b). In comparing these results with the tyrosine phosphorylation blot using the anti-phosphotyrosine antibody 4G10, we conclude that Lyn phosphorylates JAK at a site other than those found in the activation loop. Further, absent tyrosine phosphorylation of JAK1 and JAK2 at the activation loop residues in M4-stimulated DT40 cells suggests that STAT phosphorylation does not occur via JAK activation. To confirm this, we treated DT40 cells with the JAK inhibitor AG490. Short and long exposure to AG490 failed to inhibit M4-stimulated tyrosine phosphorylation of STAT1, STAT3 and STAT5 (Figure 6a -c), nor did AG490 inhibit Lyn activation (Figure 6d ). In contrast, 100 mM AG490 will block tyrosine phosphorylation of G-CSF-induced tyrosine phosphorylation of JAK2 or STAT3 in DT40GR cells (data not shown (Koay et al., 2002) ).
Effect of antisense JAKs on STAT phosphorylation by BCR and G-CSF intracellular signaling
To strengthen our findings that Lyn activated STAT via a JAK-independent mechanism, we sought to repress JAK protein expression. We cloned both JAK1 and JAK2 from the chicken DT40 cells and prepared antisense constructs. Multiple clones of DT40 cells transfected with antisense to JAK2 and JAK1 were established by limiting well dilution. Successful repression of JAKs expression was confirmed by Western blotting from cell pools representing antisense JAK2 and JAK1 clones (Figure 7a ). Repression of JAK1 or JAK2 resulted in inhibition of STAT3 phosphorylation in G-CSF-stimulated DT40GR cells, but STAT3 phosphorylation was unaffected in M4-stimulated DT40GR cells (Figure 7b ). Similar inhibition of STAT5 or STAT1 phosphorylation occurred in G-CSF-stimulated DT40GR cells (Figure 7c and d) , whereas no change Figure 5 Autophosphorylation pattern of JAK1 and JAK2 following M4 stimulation. DT40GR cells were stimulated by either M4 (5 mg/ml for 5 min) or G-CSF (100 ng/ml for 10 min). Wholecell lysates were obtained and blotted for phosphoJAK2 or phosphoJAK1 with antibodies recognizing the auto-phosphorylated sites in JAK2 (Y1007, Y1008) or JAK1 (Y1022, Y1023). of phosphorylation level of STAT5 and STAT1 followed in M4-stimulated cells.
In vitro direct phosphorylation of STAT3 by Lyn through BCR To provide evidence that Lyn directly phosphorylates STATs in vitro, we constructed a GST-STAT3 fusion protein to serve as a substrate. Murine STAT3 SH2 domain cDNA with a linker region containing tyrosine 705 was introduced into pGEX4T-1 vector to make a fusion protein GST-STAT3 þ 705 (584AA-715AA), which contains seven tyrosine residues (Tyr584, 640, 657, 672, 674, 686 and 705) , but tyrosine 686 was mutated to phenylalanine by site-directed mutagenesis. The STAT3-SH2 domain without that linker region was also fused with pGEX4T-1 and named GST-STAT3-705 (584AA-674AA). Both of them share five tyrosine residues (Tyr584, 640, 657, 672, 674) except tyrosine 705 and are easily distinguishable from each other in size by 41 amino-acids differences (Figure 8a ). As shown in Figure 8 , Lyn phosphorylates only GST-STAT3 þ 705 (Figure 8b) . Additionally, Syk, another PTK in BCR signaling was unable to directly phosphorylate STAT3 mediated by BCR (Figure 8c) . Further, treatment with the Syk inhibitor piceatannol did not affect BCRinduced tyrosine phosphorylation of STAT3 (data not shown). These data support the role of Lyn as the BCRactivated kinase that phosphorylates STATs. As sitedirected mutagenesis revealed tyrosine 705 as the critical residue for STAT3's transcriptional factor activity (Kaptein et al., 1996) , Lyn's ability to phosphorylate STAT3 would also lead to its functional activation.
Functional STAT activation by BCR engagement
To confirm that the tyrosine phosphorylation of STAT correlated with activity, we analysed the DNA binding capacity of STATs after stimulated by M4. Nuclear extracts were prepared and used for electrophoretic mobility shift assay (EMSA) with g 32 P-labeled hSIE probe that binds STAT3 and STAT1 with high affinity (Tweardy et al., 1995; You et al., 1999) . In agreement with the phosphorylation of STATs, DNA binding activity was markedly increased after M4 stimulation in wild-type cells, but absent in Lyn-null DT40 cells (Figure 9a ). Although we could not detect the antibody-mediated supershifting of STAT bands (Figure 9b and last lane of Figure 9a ), specificity was corroborated by competition with two-or fourfold cold probe that completely abrogated the binding signal (Figure 9b , lanes 5 and 6) and one STAT3 supershift (Figure 9b , lane 9).
Discussion
The STAT family of transcription factors is activated by a variety of cytokines and growth factors, each one initiating signaling pathways via their cognate receptors. Once bound, ligand-mediated receptor conformational changes occur, resulting in trans-phosphorylation and activation of the JAKs (Ihle, 1995) . In turn, activated JAKs phosphorylate particular tyrosine residues in the receptor's cytoplasmic domain. Some of these phosphorylated sites may serve as docking sites for the STAT-SH2 domains. Finally, the JAKs phosphorylate the bound STAT to trigger their dimerization and nuclear translocation, effecting DNA transcription Figure 7 Repression of JAK1 or JAK2 by antisense has no effect on BCR-induced tyrosine phosphorylation of STAT3, STAT5 and STAT1. After isolation and cloning of chicken JAK1 and JAK2, vectors were constructed with antisense sequence to JAK1 or JAK2. An empty vector pcDNA3 was used as a negative control. These constructs were electroporated into DT40GR cells. Repression of JAK2AS-1, AS-2; JAK1AS-1, AS-2 was determined by Western blotting and several ASJAK2 (clones 3, 17, 21 fromAS-1, clones 7, 14 fromAS-2, lanes 2-6) and JAK1AS-1 (clones 2, 7, 17, 22, 24, lanes 2-6) clones were shown in (a). Cells were then stimulated either by M4 or G-CSF before cell lysis. Whole-cell lysates from either G-CSF or M4-stimulated cells were blotted for phospho-STAT3 (b) or phospho-STAT5 (c) and phospho-STAT1 (d). (Finbloom and Larner, 1995; Leonard and O'Shea, 1998; Imada and Leonard, 2000) .
Compared to STAT activation by JAK in cytokine receptor signaling, few studies on STAT activation through either non-JAK PTK or antigen receptor have been reported. The most prominent example is v-Src that induces a constitutive activation of STAT3 in the absence of cytokine stimulations (Yu et al., 1995; Cao et al., 1996) . PTK other than Src, such as Lck and v-Fps/Fes activate STAT3 and STAT5 in T cells and fibroblasts, respectively (Cirri et al., 1997; Nelson et al., 1998; Lund et al., 1999) . In the mouse T-cell lymphoma cell line LYSTRA that overexpresses Lck, both DNA binding activities and tyrosine phosphorylation of STAT3 and STAT5, but not STAT1, are enhanced. Further JAK activation is constitutive (Yu et al., 1997) . In chronic myeloid leukemia, the oncogenic fusion protein BCR-ABL has been shown to activate STAT5 and STAT3, regardless of JAK activity (de Groot et al., 1999; Coppo et al., 2003) . (The BCR in BCR-ABL refers to breakpoint cluster region, not BCR.) Few reports of STAT phosphorylation by the BCR have appeared (Karras et al., 1996a, b) . Su et al. (1999) reported on STAT1 tyrosine phosphorylation following BCR engagement. Our results indicate that STAT1 phosphorylation occurs at the very early phase of anti-IgM stimulated B cells, in agreement with their findings. Moreover, we found a profound and rapid phosphorylation of STAT3 and STAT5, indicating that there is a general activation of STATs after engagement of BCR in DT40 cells.
As there are two routes leading to activation of STATs: JAK-STAT pathway and non-JAK PTK-STAT pathway, we analysed the phosphorylation activated state of the JAKs. JAK1 and JAK2 are expressed in DT40 cells as detected by Western blot and reverse transcriptase-polymerase chain reaction (data not shown). Although a previous report found no JAK activation after BCR engagement (Saouaf et al., 1994) , we observed JAK phosphorylation in a cell line extensively used for BCR signaling (Kurosaki et al., 2000) . In combination with the tyrosine-specific phosphoantibodies toward the activation loop of JAK1 or JAK2, we conclude that the phosphorylation signal comes from tyrosine residues outside the activation loop. The physiological significance of these tyrosine phosphorylation events is not well known. Recent studies have identified the pseudokinase domain JH2 of JAK2 negatively regulates its activity (Saharinen et al., 2003) . Tyrosine phosphorylation of the JAKs outside of their activation loop may permit the JAK to serve as a docking site for proteins with phosphotyrosine binding domains.
With the use of Lyn-null DT40 cell line, we showed that the phosphorylation and activation of STAT through BCR is Lyn-dependent. As an Src kinase member mainly expressed in B and myeloid lineages (Yi et al., 1991) , it is plausible that Lyn phosphorylates and activates STAT in a JAK-independent manner. In support of this hypothesis, Lyn plays a role in erythropoietin-induced tyrosine phosphorylation of STAT5 (Okutani et al., 2001) . Recognizing that Lyn is the only Src kinase present in DT40 cells (Takata et al., 1994) , we found that gene ablation and Src kinase inhibition resulted in absent or reduced phosphorylation of STAT. A kinase-inactive, dominant-negative Lyn gave results similar to those when a dominant-negative Src interfered with STAT5 phosphorylation following erythropoietin receptor signaling (Okutani et al., 2001) . The Src kinases can directly phosphorylate the STATs, as evidenced by Lyn phosphorylating STAT3 at tyrosine 705 in vitro in a BCR-dependent manner. However, the phosphorylation of STATs mediated by Lyn through BCR is transient. We ascribe this to Lyn's dual role in both positive and inhibitory regulation of BCR signaling (Hibbs et al., 2002) that results in balance between PTKs and protein tyrosine phosphatases (Ishikawa et al., 2002; Pereira and Lowell, 2003) , so the functional consequences of Lyn-mediated STATs activation remain undetermined and needs further study. Transient activation by Lyn may result in a different set of genes transcribed than more sustained activation by the JAKs. An important conclusion is that JAK-STAT and Lyn-STAT pathways are independent of each other. We have previously shown that JAK-STAT pathway is intact in G-CSF-mediated signaling in both wild-type and Lyn-null cells (Corey et al., 1998) . In this study, we found G-CSF-mediated STAT phosphorylation is not Lyn-dependent by means of antisense JAK or AG490 inhibition experiments. Consistent with this, overexpression of dominant-negative JAK2 had no effect on Srcmediated phosphorylation of STATs (Chaturvedi et al., 1998) . Combined with our results, this suggests that two independent pathways exist that mediate STAT activation, one dependent on the JAKs and the other dependent on Src kinases. There might be some distinctive features between these two pathways. For instance, prolonged stimulation through BCR can activate STAT3 via phosphorylation of S727, but no such change occurred in G-CSF-stimulated cells (data not shown). Distinctions in the kinetics and specificity of STAT activation pathways remain to be elucidated. The combination of cytokines stimulation and antigendriven BCR activity may drive specific B-cell fate in the germinal center. There, STAT5 may play a special role in the self-renewal of B cells (Scheeren et al., 2005) . The delayed activation of STAT after BCR engagement could be secondary to interleukin (IL)-6 or CD40L production, because neutralizing antibodies to IL-6 or CD40 inhibited STAT3 activation following BCR engagement (Fan and Rothstein, 2001 ). B-cell stimulation of STAT3 by phorbol ester and calcium ionophore did not require IL-6, and neither had any effect on STAT1. It is not known whether these stimuli activate STATs via JAK or Src family kinases.
In conclusion, our results reveal that Lyn contributes significantly to BCR-dependent STAT activation, in part through direct phosphorylation of a STAT, for example, STAT3. Lyn-mediated STAT activation through BCR is JAK-independent, implying the existence of two distinctive STAT activation pathways independent of each other, and therefore possibly conducting different functions. In B-lymphocyte signaling, STAT activation can occur via BCR and Lyn. As demonstrated recently, Lyn could be another potential pharmacological target in the suppression of aberrant STATs activation that arises in many malignancies and autoimmune disorders (Sternberg and Gilliland, 2004; Yu and Jove, 2004) .
Materials and methods
Cells and reagents DT40, DT40GR and Lyn-null DT40 cells have been described elsewhere (Takata et al., 1994; Corey et al., 1998) . DT40 cell lines were maintained in RPMI, supplemented with 10% fetal calf serum, 2% chicken serum, 200 mM L-glutamine and penicillin/streptomycin. The Src kinase inhibitor PD173952 was provided by Dr Alan Kraker (Parke-Davis, Ann-Arbor, MI, USA), The JAK inhibitor AG490 was purchased from BIOMOL (Plymouth Meeting, PA, USA). Antibodies employed in the experiments were: anti-chicken IgM antibody M4 (Southern Biotech, Birmingham, AL, USA); Lyn, JAK1, JAK2, STAT1 and Syk from Santa Cruz Biotech (Santa Cruz, CA, USA); anti-phosphotyrosine mAb 4G10, STAT3, STAT5b and phospho-JAK2 (Y1007, Y1008) from Upstate (Lake Placid, NY, USA), phospho-STAT3 (Y705), phospho-STAT1 (Y701), phsopho-STAT5 (Y694) and phospho-Src (Y416) from Cell Signaling Tech (Beverly, MA, USA); phosphoJAK1 (Y1022, Y1023) from Sigma (St Louis, MO, USA) and anti-GST antibody from Amersham (Piscataway, NJ, USA).
Expression vectors and transfections
The kinase inactive form of Lyn (LynK275R) was described previously (Corey et al., 1998) . Antisense for chicken JAK2 and chicken JAK1 were amplified from DT40 cDNA by the following primers and subsequently cloned into pcDNA3.0 in reverse orientation: chicken JAK2 AS-1 (1AA-111AA): sense: 0 . All transfections were performed by electroporating 10 mg of the above constructs or empty pcDNA3.0 vector (control) into DT40 cell lines at 300 V, 1000 mF by using Bio-Rad Gene PulserII. The transfectants were selected with neomycin. The murine STAT3-SH2 domain with or without tyrosine residue 705 was fused with pGEX-4T1 and transformed into BL21 for IPTG induction. The fusion protein was purified and eluted by GST-glutathione affinity chromatography.
Immunoblotting and immunoprecipitation
Following stimulation with M4 (5 mg/ml), or G-CSF (100 ng/ ml, Neupogen, Amgen, Thousand Oaks, CA, USA), cells were lysed in 1% NP40 buffer containing 137 mM NaCl, 10 mM Tris, pH 8.0 and 1 mM ethylenediamenetetraacetic acid. Fresh cocktail solution of protease inhibitors (Sigma) and tyrosine phosphatase inhibitor 2 mM sodium vanadate were added. Cells were lysed for 45 min, and post-nuclear supernatants obtained by centrifugation at 12 000 r.p.m. for 15 min at 41C. For immunoprecipitation, the precleared lysates were incubated overnight with indicated antibodies, then adsorbed by Protein A/G agarose (Santa Cruz) for another 2 h, then washed four times with lysis buffer, mixed with 2 Â Laemmli reducing buffer for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The cell lysates or protein immunoprecipitates were resolved by SDS-PAGE and then electroblotted onto a polyvinlylidene difluoride membrane (Millipore, Bedford, MA, USA). The blots were incubated with appropriate antibodies and visualized with enhanced chemiluminescence detection kit (ECL, Amersham).
In vitro phosphorylation assay and in vitro Lyn kinase assay In vitro phosphorylation assay was performed as described elsewhere (Chin et al., 1998) . Briefly, immunoprecipitates were incubated with kinase buffer (25 mM HEPES, pH 7.5, 100 mM NaCl, 5 mM MgCl 2 , 10mM MnCl 2 ) with or without cold adenosine 5 0 triphosphate (ATP). GST-STAT3-SH2 protein (2.5 mg) with or without Tyr705 was added as a substrate at 251C for 30 min then boiled in 2 Â reducing buffer for 5 min. Samples were loaded on SDS-PAGE, transferred onto polyvinylidine difluoride membrane and detected by blotting with anti-phosphotyrosine antibody. The in vitro Lyn kinase assay was performed as described elsewhere by us (Corey et al., 1998) .
Electrophoretic mobility shift assay
The procedures for nuclear extract preparation and EMSA were conducted as described previously (Tweardy et al., 1995) . Oligonucleotides corresponding to hSIE (high affinity sis-inducible element, m67 variant, 5 0 -TCATTTCCCGTAAA TCCCTA-3 0 ), that avidly bind STAT3 and STAT1, were endlabeled by [g- 32 P]ATP (3000 mCi/ml, Amersham). Competition EMSA was performed by adding unlabeled cold probe into nuclear extracts before adding radioisotope-labeled probe. A supershift assay was done with anti-STAT polyclonal antibody by preincubation of nuclear extracts with antibodies for 30 min at room temperature before addition of probe.
